Abstract 588P
Background
HER2 alterations in non-small cell lung cancer (NSCLC) are recognized as challenging therapeutic targets with unmet clinical needs. While the recent advent of HER2 ADC has shown some clinical benefits, its efficacy in real-world clinical settings remains largely uncharted. Thus, we conducted a multi-center retrospective study to assess the efficacy of HER2 ADC in a real-world context.
Methods
We continuously enrolled patients with ERBB2-altered NSCLC who underwent monotherapy or combination therapy with Disitamab Vedotin (RC48) between August 2021 and March 2023.
Results
A total of 22 patients with HER2 alterations were enrolled, including 15 with HER2 mutations, 5 with HER2 amplifications, and 2 with both. The overall objective response rate (ORR) was 45.5% (10/22), disease control rate (DCR) was 90.9% (20/22), and median progression-free survival (mPFS) stood at 7.5 months (95% CI 6.6-8.4 months). 95.5% of patients (21/22) underwent combination therapy, yielding an ORR of 47.6% (10/21). Combination regimens includes platinum, anti-angiogenesis, HER2 TKIs, and PD-1/PD-L1 inhibitors. Of note, the platinum-based combination regimen shows the highest ORR at 71.4% (5/7), following is HER2-TKI at 50% (4/8). First-line treatment patients experienced an ORR of 62.5% (5/8), whereas second-line and third-line or beyond treatments demonstrated ORRs of 57.1% (4/7) and 14.3% (1/7) respectively. No significant difference in mPFS was observed between 1L and 2L or subsequent treatments. The mPFS was notably prolonged in HER2-amplified patients and anti-HER2 naïve patients.
Conclusions
For HER2-altered NSCLC patients, RC48 combined therapies are applicable treatment options, particularly with platinum agents. RC48 combined therapies also offers a new treatment approach for patients with HER2 amplification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract